In vivo studies have shown that the novel targeted nanocarrier could effectively ablate tumors with a synergistic PDT/PTT effect, and further induce the release of tumor-related pro-inflammatory mediators (TNF-α, IFN-γ, IL-12, CTL), resulting in systemic anti-tumor immunity and secondary death of tumor cells. The gene discussed is TNF; the disease is neoplasm.